CRL•benzinga•
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
Summary
Charles River's Q4 revenue topped estimates despite a 1.1% decline. The company forecasts a revenue drop in 2025, with biotech demand expected to stabilize.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 19, 2025 by benzinga